Outcomes of acute respiratory distress syndrome in COVID-19 patients compared to the general population: a systematic review and meta-analysis.
Adam Andrew DmytriwRicha ChibbarPetty Pin Yu ChenMichael D TraynorDong Wook KimFernando Pereira BrunoChristopher C CheungAnuj PareekAndrew Chia Chen ChouJeffrey GrahamMahmoud DibasGeeta ParanjapeNatalie L ReiersonShelby KamrowskiJacob RozowskyAveri BarrettMegan SchmidtDisha ShahaniKathryn CowieAmber R DavisMohamed AbdelmegeedJillienne C TouchetteKevin M KallmesJohn Michael PedersonPraneeth Reddy KeesariPublished in: Expert review of respiratory medicine (2021)
Ten studies with 2,281 patients met inclusion criteria (COVID-19: 861 [37.7%], ARDS: 1420 [62.3%]). There were no significant differences between the COVID-19 and ARDS groups for median number of mechanical ventilator-free days (MDM: -7.0 [95% CI: -14.8; 0.7], p = 0.075), ICU LOS (MD: 3.1 [95% CI: -5.9; 12.1], p = 0.501), hospital LOS (MD: 2.5 [95% CI: -5.6; 10.7], p = 0.542), or all-cause mortality (OR: 1.25 [95% CI: 0.78; 1.99], p = 0.361). Compared to the general ARDS population, results did not suggest worse outcomes in COVID-19-related ARDS.
Keyphrases
- acute respiratory distress syndrome
- mechanical ventilation
- sars cov
- coronavirus disease
- extracorporeal membrane oxygenation
- end stage renal disease
- ejection fraction
- respiratory syndrome coronavirus
- newly diagnosed
- intensive care unit
- molecular dynamics
- chronic kidney disease
- healthcare
- peritoneal dialysis
- prognostic factors
- type diabetes
- adverse drug
- insulin resistance
- skeletal muscle
- glycemic control